Work

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Year: 2014

Type: article

Study design: Clinical Trial

Source: Targeted Oncology

DOI: 10.1007/s11523-014-0320-2

Authors: Irene Brana, Antonio Calles, Patricia M. LoRusso, Lorrin K. Yee, Thomas A. Puchalski, Shobha Seetharam, Bob Zhong, Carla J. de Boer, Josep Tabernero, Emiliano Calvo

Institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Spanish National Cancer Research Centre, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Northwest Medical Specialties, Janssen Research & Development (United States), Janssen (Netherlands)

Language: English

Topic: Chemokine receptors and signaling

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Scientific Affairs

OpenAlex ID: W2093886651

FWCI: 4.452

Cites: 33

Cited by: 216

Related to: 10